# Mogamulizumab Q4week Dosing in Participants With R/R CTCL

> **NCT04745234** · PHASE2 · UNKNOWN · sponsor: **Kyowa Kirin, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma, Relapsed
- Cutaneous T-Cell Lymphoma Refractory

## Interventions

- **DRUG:** Mogamulizumab

## Key facts

- **NCT ID:** NCT04745234
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-16
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04745234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04745234, "Mogamulizumab Q4week Dosing in Participants With R/R CTCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04745234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*